drugset / Trial / NCT05365893
PHL Treatment in Pancreatic Cancer
Phase 0
Active not recruiting
20 enrolled
Fox Chase Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This proposal will investigate the effect of paricalcitol, hydroxychloroquine, and losartan (PHL) combination of 3 stroma-modifying drugs on pancreatic adenocarcinoma and its stroma.
Timeline
- Start
- 2021-10-20
- Primary completion
- 2025-12-18
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 600 mg | Oral |
| Subject | Losartan | Other / unclassified | 50 mg | Oral |
| Subject | Paricalcitol | Other / unclassified | 25 ug | Intravenous |